Q&A: ABX464 for treatment of UC seen as ‘novel mechanism of action’

Abivax announced updates on ABX464 for the management of moderate to severe ulcerative colitis, according to a company press release.Healio Gastroenterology spoke with Bruce E. Sands, MD, MS, the Dr. Burrill B. Crohn professor of medicine at the Icahn School of Medicine at Mount Sinai, about key results from the phase 2b trial of ABX464.Healio: Can you discuss the design of the study?Sands: The phase 2b clinical trial in patients with moderate to severe UC consists of two parts: a 16-week induction phase (primary endpoint at week 8), where three different daily doses (25 mg, 50 mg or 100 mg)Read More

Share on facebook
Share on twitter
Share on linkedin